WYE-125132

WYE-125132

Biochem/physiol Actions

In ovarian cancer cells, WYE-132 might prevent the activity of sphingosine kinase-1 (SphK1), leading to pro-apoptotic ceramide production.

WYE-125132 (WYE-132) is a highly potent, ATP-competitive, and specific inhibitor of mTOR with an IC50 value of 0.19 nM. Unlike rapamycin, which ihibits mTOR through allosteric binding to mTOR complex 1 (mTORC1) only, WYE-132 inhibits both mTORC1 and mTORC2. WYE-125132 is >5000-fold selective for mTOR vs. phosphoinositide 3-kinase (PI3K). WYE-132 induced apoptosis in a variety of cancer lines including LNCap prostate cells and H1975 lung cancer cells. WYE-132 also inhibited ovarian cancer cell growth.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Kinase Phosphatase Biology research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3573745 WYE-125132 white to beige 100 SIGMA-ALDRICH −20°C
£502.82 (exc VAT) per 25MG
-
+
3573746 WYE-125132 white to beige 100 SIGMA-ALDRICH −20°C
£124.94 (exc VAT) per 5MG
-
+